花旗发表研究报告指，微创医疗的基本面持续改善，因此已重新覆盖该股，予"买入"评级和目标价16港 元，并列为行业首选股之一。报告提到，微创医疗2025年上半年净亏损按年收窄66%，该行预计公司将 在2025年下半年录得盈利。另外，该行预期高增长的海外平台将在2025年按年实现70%至80%，且增长 趋势或在2026年持续。公司亦获得合并后的协同效应，将成为公司的上行潜力。 ...

Summary of Key Points from the Conference Call Industry Overview - **Industry**: China Healthcare - **Outlook**: The healthcare industry is expected to experience growth driven by supportive policies, innovation, and the expansion of commercial insurance, which will create a sustainable growth environment starting in 2026 [1][2][10]. Core Insights and Arguments 1. **Speculative Rally and Fundamentals**: The rally in the first half of 2025 was driven by speculators, but long-term investors are returning due to improved fundamentals in the second half of 2025 [1]. 2. **Commercial Insurance Expansion**: The commercial health insurance market is projected to expand significantly, potentially covering 30% of national direct medical expenditures, which could lead to a 3-5x growth in the domestic innovative drug market [2][9][10]. 3. **Government Support for Biopharma**: The Chinese government is positioning biopharma as a strategic pillar industry, with initiatives like the National Venture Fund of Rmb100 billion to support innovative drug development [2][17]. 4. **Bio-manufacturing Growth**: China's bio-manufacturers are expected to strengthen their market position due to favorable US/China policies and increased clinical trial activities [3][54]. 5. **Medtech Expansion**: Medtech leaders are anticipated to grow through product upgrades and overseas market expansion, with companies like Mindray and MicroPort Scientific being key beneficiaries [4]. 6. **Impact of DRG Policies**: The worst impacts of Diagnosis-Related Group (DRG) policies are expected to be over, with hospitals likely to see revenue recovery starting in the second half of 2025 [6]. 7. **AI Integration in Healthcare**: Larger hospitals are budgeting significant amounts for AI technologies, which is expected to benefit online healthcare platforms [5]. Additional Important Insights 1. **Clinical Trial Growth**: There has been a notable increase in clinical trial numbers in China, particularly for innovative drugs, which is expected to continue into 2026 [59][60]. 2. **Prescription Trends**: A significant shift is occurring in prescription patterns, with generics dominating public prescriptions and online platforms benefiting from prescription outflow [65][70]. 3. **Investment in Innovative Drugs**: The financing for innovative drugs in China has seen a substantial increase, with total financing reaching Rmb102.6 billion in 2025, marking a 38% increase [43]. 4. **Geopolitical Considerations**: There are minimal concerns regarding the geopolitical landscape affecting the biotech sector, although the upcoming announcement of the 1260H list may cause short-term volatility [64]. Top Investment Picks - **Pharma/Biotech**: Hengrui, Ascletis, Abbisco, Wuxi Apptec, Tigermed, Hygeia, SSY, AliHealth, Yidu Tech [2][3][4][5][6][10]. - **Medtech**: Mindray, United Imaging, MicroPort Scientific [4]. This summary encapsulates the key points discussed in the conference call, highlighting the growth potential and strategic shifts within the China healthcare industry.

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The treatment equipment industry in China has experienced significant growth, with the market size increasing from 375.23 billion RMB in 2019 to 621.39 billion RMB in 2023, reflecting a compound annual growth rate (CAGR) of 13.44% [9] - The market is expected to continue growing, with projections indicating an increase to 872.09 billion RMB by 2028, at a CAGR of 6.12% [10] - The integration of AI and advanced technologies is driving innovation and efficiency in treatment devices, enhancing diagnostic accuracy and treatment precision [31] Market Background - The medical device sector includes instruments and software for diagnosis, monitoring, and treatment, with a notable increase in clinical trial institutions from 1,176 in 2022 to 1,340 in 2023, a growth of 13.8% [5] - The treatment equipment category encompasses surgical instruments and rehabilitation devices, which are crucial for patient recovery [6][7] Market Status - The treatment equipment market is expanding due to improved regulatory frameworks and increased domestic innovation, with a total of 13,260 medical device registrations in 2023, a 25.4% increase from 2022 [9] - The demand for treatment devices is rising, driven by an aging population and increased surgical procedures, with PCI surgeries growing from 915,000 in 2018 to 1,636,000 in 2023, a 26.4% year-on-year increase [13] Market Competition - The competitive landscape features a tiered structure, with leading companies like Mindray Medical and MicroPort in the first tier, and others like Qizhi Laser and Yuyue Medical in subsequent tiers [17][18] - The total R&D investment among the top 20 listed medical device companies reached 11.18 billion RMB in 2023, up 14.9% from 2022, indicating a strong focus on innovation [18] Recommended Brands - Mindray Medical is recognized for its leadership in ultrasound imaging and life information support, with a significant market share in high-end ultrasound products [19] - MicroPort specializes in minimally invasive intervention technologies, particularly in cardiovascular and neurological fields [20] - Yuyue Medical leads in home medical devices, with a dominant market position in respiratory therapy and blood glucose monitoring [22] Development Trends - The industry is undergoing a technological revolution with AI, 5G, and IoT integration, enhancing diagnostic and treatment capabilities [31] - The shift towards tiered medical services is optimizing the structure of healthcare consumption, with increased procurement of high-end devices by tertiary hospitals [32] - National policies are fostering domestic innovation and internationalization in the medical device sector, with a focus on streamlining approval processes for innovative products [33]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總 ...

Group 1 - The core point of the article is that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 3.31 million shares on January 5, 2026, with a total net increase of 16.43 million shares over the past five trading days [1] - Over the last 20 trading days, there were 7 days of net reductions in holdings, totaling 1.05 million shares [1] - As of now, southbound funds hold 899 million shares of MicroPort Medical, accounting for 46.96% of the company's total issued ordinary shares [1] Group 2 - The total number of shares held by southbound funds on January 5, 2026, was 899 million, reflecting a change of 3.31 million shares, which is a 0.37% increase [2] - The previous trading days showed significant changes, with an increase of 9.10 million shares (1.03%) on January 2, 2026, and smaller increases on December 30, 2025 (0.28%), December 29, 2025 (0.16%), and December 23, 2025 (0.02%) [2] - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices, operating through eight divisions including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, and surgical robotics [2]

Group 1 - The brain-computer interface sector experienced a strong surge on the first trading day of A-shares in 2026, with stocks like Botao Bio, Sino Medical, and Xiangyu Medical hitting the daily limit of 20% increase, leading to a 5.6% rise in the medical device ETF [1] - Elon Musk announced on social media that his brain-computer interface company Neuralink will begin "mass production" of brain-computer interface devices in 2026 [1] - In 2025, China approved 76 innovative drugs for market launch, significantly surpassing the 48 approved in 2024, marking a historical high [1] Group 2 - The medical device ETF (562600) rose by 5.65%, tracking the CSI All-Share Medical Device Index, with a high industry representation of 89% and a brain-computer interface content of 23.14%, outperforming other medical ETFs [1] - The Hang Seng Medical ETF (159892) increased by 6.07%, with a latest scale of 5.564 billion yuan, featuring top-weighted stocks such as BeiGene, WuXi Biologics, and CanSino Biologics [2] - The Hong Kong Stock Connect Medical ETF (520510) rose by 5.72%, leading the market in CXO concentration, with key stocks including WuXi Biologics, MicroPort, and JD Health [2]

Market Overview - A-shares continued to experience fluctuations with major indices showing recovery in volume, supported by a significant increase in weekly financing, which rose substantially compared to the previous period[2] - Stock ETFs saw a net inflow of 363.41 billion yuan, indicating positive market sentiment following the Central Economic Work Conference held in December[2] - By December 31, the major broad-based indices showed a cautious outlook, with only the CSI 500 maintaining a bullish signal, while other indices shifted to a more cautious stance[2] Fixed Income Insights - In the period from December 29 to December 31, 2025, a total of 76 credit bonds were issued, amounting to 769.14 billion yuan, reflecting an 82.02% decrease from the previous week[33] - The secondary market for publicly listed REITs experienced a decline, with returns ranking from high to low as follows: pure bonds > A-shares > convertible bonds > REITs > US stocks > crude oil > gold[31] Industry Highlights - Lithium prices reached approximately 112,000 yuan per ton, with recommendations to focus on companies with cost advantages and resource expansion potential, such as Tianqi Lithium and Ganfeng Lithium[7] - The copper smelting capacity in China may face restrictions due to regulatory measures, while the demand for copper remains under pressure despite a tight supply outlook for 2026[7] Consumer and Economic Policies - The first batch of "old-for-new" subsidy funds for 2026 is expected to be lower than the previous year, with an estimated total scale of 250 billion yuan, potentially boosting retail sales growth by 1.2 percentage points[13] - The PMI returned to the expansion zone in December, supported by effective incremental policies and a favorable export environment, indicating a positive economic outlook for the end of the year[15]

Group 1 - The core viewpoint of the articles highlights a significant surge in the Chinese innovative drug sector, with license-out transactions exceeding $130 billion, marking a year-on-year increase of over 150% and surpassing 50% of the global total for the first time [1] - The cash flow generated from business development (BD) and the IPO boom is providing ample funding for research and development, which is crucial for the industry's future growth [1] - Three main driving forces for the industry in 2026 are identified: commercialization realization, clinical data validation, and improvement of payment systems, which are expected to usher in a new era of "value realization" [1] Group 2 - The Hang Seng Medical ETF (159892) focuses on innovative drugs, CXO, and related industries, benefiting from the advantages of the Hong Kong Stock Exchange's 18A system, which covers numerous innovative targets [2] - The ETF is expected to continue its valuation recovery trend under the catalysts of innovative drug exports and commercial insurance directories [2]

机构：光大证券 研究员：吴佳青 事件：公司近期公告1）根据微创医疗集团会计政策其无法控制微创脑科学但仍对其保持重大影响力， 故终止合并微创脑科学，构成须予披露交易。2）微创心通召开股东大会，审议通过并购微创心律管理 有限公司的重大资产重组议案。此次并购将推动微创医疗旗下结构性心脏病与心律管理两大核心业务板 块的深度整合。 点评： 盈利预测与评级：综合考虑集采影响、公司降低各项费用、聚焦核心业务等因素，我们预计公司有望实 现持续减亏，我们上调25~26 年净利润预测为-30/96 百万美元（原值为-59/91 百万美元），新增27 年净 利润预测为133 百万美元。公司为国内高值耗材领军企业，研发实力强劲，维持"买入"评级。 风险提示。高值耗材降价超预期、骨科减亏低于预期、收购整合风险等。 治理结构改善注入新动能，出海业务成为核心增长引擎。公司治理层面，上实资本旗下基金成为公司重 要战略股东，有望在治理和业务发展方面注入新动能。公司近期完成心律管理与结构性心脏病业务的重 组，旨在打造综合心脏病平台，新公司将融合微创心律管理的AI 诊断及算法技术，与微创心通在结构 性心脏病介入治疗、输送系统及生物材料方面的技术积 ...

微创脑科学（02172）盘中涨超5%，截至发稿，股价上涨3.77%，报11.29港元，成交额637.89万港元。 微创医疗公布，终止合并微创脑科学，原因是微创脑科学在委任一名独立非执行董事后，公司根据会计 政策认为无法控制微创脑科学但仍保持重大影响力。终止合并预期将确认视同处置附属公司收益。 责任编辑：卢昱君 微创脑科学（02172）盘中涨超5%，截至发稿，股价上涨3.77%，报11.29港元，成交额637.89万港元。 微创医疗公布，终止合并微创脑科学，原因是微创脑科学在委任一名独立非执行董事后，公司根据会计 政策认为无法控制微创脑科学但仍保持重大影响力。终止合并预期将确认视同处置附属公司收益。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 责任编辑：卢昱君 ...